261280523 Stock Overview
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$10.07 |
| 52 Week High | NT$0 |
| 52 Week Low | NT$0 |
| Beta | 0.57 |
| 1 Month Change | 0% |
| 3 Month Change | -1.70% |
| 1 Year Change | -16.45% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 261280523 | LU Biotechs | LU Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | -4.6% |
| 1Y | -16.5% | -10.3% | -0.4% |
Return vs Industry: 261280523 underperformed the Luxembourg Biotechs industry which returned -11.4% over the past year.
Return vs Market: 261280523 underperformed the Luxembourg Market which returned 1.5% over the past year.
Price Volatility
| 261280523 volatility | |
|---|---|
| 261280523 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in LU Market | 6.0% |
| 10% least volatile stocks in LU Market | 4.0% |
Stable Share Price: 261280523 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 261280523's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 261280523 fundamental statistics | |
|---|---|
| Market cap | US$2.91b |
| Earnings (TTM) | -US$19.14m |
| Revenue (TTM) | US$156.67m |
19.2x
P/S Ratio-157.2x
P/E RatioIs 261280523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 261280523 income statement (TTM) | |
|---|---|
| Revenue | NT$5.11b |
| Cost of Revenue | NT$610.54m |
| Gross Profit | NT$4.50b |
| Other Expenses | NT$5.12b |
| Earnings | -NT$623.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.88 |
| Gross Margin | 88.04% |
| Net Profit Margin | -12.22% |
| Debt/Equity Ratio | 0.4% |
How did 261280523 perform over the long term?
See historical performance and comparison